Prioritizing Specific Areas of Interest
- Medical Devices, Tools, and Diagnostics
- Gene Therapy / Gene Editing
- Cell therapies
- Small molecules
- Rare disease
ABC Investment Approach
We are most interested in technologies and products that are being developed to meet patient and clinician demands and improve on current treatment options. Ideal companies and product candidates have the potential for “best- or first-in-class” positioning.
Our investment strategy is first and foremost evidence-based, with a strong preference for proprietary technologies and assets that represent advances in science. We value the ability to disrupt, coupled with strong protections such as an intellectual property advantage or other barriers to entry.
Proven and effective leadership is a core component of our investment criteria. We believe that management teams with public company experience and prior successes in product development are often best positioned to deliver impactful and positive results.